The Challenges of Implementing Screening Programs Across Cancer Types

Dr. Verna Mai
Director, Screening Programs

International Breast Cancer Screening Network
Biennial Meeting

May 11–12, 2006
Objectives of Presentation

From the Canadian perspective:
• What is the current situation with regard to implementation of screening programs across cancer types (breast, cervix, colorectal) and why is this an issue, now?
• What are the factors that support the implementation of programs across cancer types?
• What are the barriers to implementation of programs across cancer types?
• Where does that leave us?? ……opportunities for action and “must do’s” to ensure programmatic screening is supported
• 13 provinces and territories – each is responsible for the provision of health care services

• Population Estimate January 2006: 32,422,919

• Largest population: Ontario (12,599,364)

• Smallest population: Nunavut (30,245)

• 7/13 have cancer agencies/boards to plan and oversee cancer services
## Canadian Cancer Statistics 2006

(Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Provincial/Territorial Cancer Registries, Public Health Agency of Canada)

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th># Deaths</th>
<th>Mortality rate per 100,000</th>
<th># New Cases</th>
<th>Incidence Rate per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal</td>
<td>4600 (M)</td>
<td>27 (M)</td>
<td>10,800 (M)</td>
<td>62 (M)</td>
</tr>
<tr>
<td></td>
<td>3900 (F)</td>
<td>17 (F)</td>
<td>9,100 (F)</td>
<td>41 (F)</td>
</tr>
<tr>
<td>Breast</td>
<td>5300 (F)</td>
<td>23 (F)</td>
<td>22,200 (F)</td>
<td>106 (F)</td>
</tr>
<tr>
<td>Cervix</td>
<td>390 (F)</td>
<td>2 (F)</td>
<td>1,350 (F)</td>
<td>8 (F)</td>
</tr>
</tbody>
</table>
Definition of Screening

“the presumptive identification of unrecognized disease or defect by the application of tests, examinations or other procedures which can be applied rapidly to sort out apparently well persons who probably have a disease from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment.” (Commission on Chronic Illness, 1951)
<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Effectiveness of Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast</strong></td>
<td>25% reduction in mortality with regular screening in 50-69 year olds</td>
</tr>
<tr>
<td><strong>Cervical</strong></td>
<td>90% is preventable with regular Pap tests</td>
</tr>
<tr>
<td><strong>Colorectal</strong></td>
<td>16% reduction in mortality with regular screening with FOBT, 20% reduction in incidence with regular screening</td>
</tr>
</tbody>
</table>
What about screening programs for these 3 cancer types?

• Breast screening programs are the most established; most (12/13) Canadian provinces and territories have programs – with key organized program components; variation across programs

• Cervical screening programs are less completely developed; active efforts underway in most jurisdictions to implement components of programmatic screening (e.g. personalized invitations,);

• Colorectal screening programs – none established – when??

Any Integration across Cancer types happening?
Why is the implementation of screening programs across cancer types an issue today?

• Funding issues, streamlining of efforts, women’s health focus, all lead to questions re: integrated cervical/breast screening programs.
  – Annual # of deaths: Breast cancer: 5300 vs. Cervical cancer: 390

• Recommendations for colorectal cancer screening programs -- can we reduce costs by combining screening infrastructures?

• Other areas of cancer control are integrated – systemic therapy (chemotherapy programs); radiation; cancer prevention

• Other integration is planned in the health care system for chronic disease prevention - address common preventable risk factors.

• Greater interest in cancer screening today than 10 years ago, leading to more questions re: why programs are not available equally for all sites; also - why is an organized program needed?
What factors that support the implementation of programs across cancer types?
What factors that support the implementation of programs across cancer types?

• **Principles of Screening/ elements of organized screening programs** are common for all screening, regardless of site.
Basic Principles of Screening
(Wilson and Jungner, 1968)

1. The condition being screened for should be an important health problem.

2. There should be an accepted treatment for patients with recognized disease.

3. Facilities for diagnosis and treatment should be available.

4. There should be a suitable test or examination, in terms of sensitivity and specificity.

5. The test should be acceptable to the population.
Principles of Screening (Cont’d)

6. The natural history of the condition, including development from latent to declared disease, should be adequately understood, including knowledge that there is a recognizable latent or early symptomatic stage during which treatment is more successful.

7. There should be an agreed upon policy concerning whom to treat as patients.

8. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.

9. Screening should be a continuous process and not a “one-time only” event.
Key Elements of an Organized Population Cancer Screening Program

Screening Working Group of the Canadian Strategy for Cancer Control

- High quality, supported by minimum standards, evidence-based guidelines and promotion of best practice.

- Continuous monitoring and evaluation. The program must have the capacity to change its programmatic elements based on the results of evaluation.

- The program must have the capacity to modify screening standards, guidelines and best practices based on new scientific evidence.

- Screening programs must adopt a culture of continually striving to increase the benefits and minimize the harms of screening.
Key Elements of an Organized Population Cancer Screening Program

- Screening must be **comprehensive**, including recruitment, recall, follow-up and timely assessment of people with positive tests.

- Screening must be supported by **public education** and **education of health care providers**.

- All eligible people should have **reasonable access** to screening, diagnostic assessment and treatment.

- Participation in a screening program should be on the **basis of a realistic understanding of the harms and benefits** of screening and the manner in which health information will be managed.
Key Elements of an Organized Population Cancer Screening Program

- The program must be supported by an **effective and efficient computerized information system** designed to accommodate the needs for confidentiality and information sharing.

- There must be **adequate resources** (financial, physical, human and informational) to support all aspects of screening.

- Screening programs must **include a consumer perspective** in all aspects of their planning and operations.
Effectiveness of Programmatic Screening

Niemenen, Kallio, Anttila and Hakama case-control study (Int. J. Cancer, 1999):

<table>
<thead>
<tr>
<th>COMPARISON OF TYPE OF CERVICAL SCREENING</th>
<th>Activity</th>
<th>Adjusted Odds Ratio (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Organized Mass Screening</td>
<td>0.38 (0.26 – 0.56)</td>
</tr>
<tr>
<td></td>
<td>Spontaneous Pap Smears</td>
<td>0.82 (0.53 – 1.26)</td>
</tr>
</tbody>
</table>

Organized Breast Screening (World Health Organization, 2002)

The evidence from randomized trials inviting women aged 50-69 to screening with mammography show that mortality from breast cancer is reduced by 25%.

Estimates made in some European countries with organized breast screening programs suggest that 20% reduction in mortality can be expected in the long term, taking into account the time it takes to achieve full implementation of national programmes and see the impact of regular screening.

Organized screening programs are more effective in reducing the rate of death from breast cancer than sporadic screening of selected groups of women.
What factors that support the implementation of programs across cancer types?

- Common principles have lead to the development of common indicators of performance, which are well known to the screening experts, but less understood by others
### Result of a Hypothetical Screening Test

<table>
<thead>
<tr>
<th>DISEASE PRESENT</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>True Positive</td>
<td>False Positive</td>
</tr>
<tr>
<td>Negative</td>
<td>False Negative</td>
<td>True Negative</td>
</tr>
</tbody>
</table>

#### Sensitivity

\[
\text{Sensitivity} = \frac{\text{True Positives (TP)}}{\text{True Positives (TP)} + \text{False Negatives (FN)}} \times 100\%
\]

#### Specificity

\[
\text{Specificity} = \frac{\text{True Negatives (TN)}}{\text{True Negatives (TN)} + \text{False Positives (FP)}} \times 100\%
\]

#### Positive Predictive Value

\[
\text{Positive Predictive Value} = \frac{\text{True Positives (TP)}}{\text{True Positives (TP)} + \text{False Positives (FP)}} \times 100\%
\]

#### Negative Predictive Value

\[
\text{Negative Predictive Value} = \frac{\text{True Negatives (TN)}}{\text{True Negatives (TN)} + \text{False Negatives (FN)}} \times 100\%
\]
Program Success Indicators

- Coverage
- Rescreening
- Quality of screening test
- Follow-up of abnormal results
- Quality of screening diagnosis
- Impact on cancer occurrence

- % of target population screened
- % of individuals (with a negative screen) rescreened within a reasonable time period
- % of screening tests rated unsatisfactory
- % of individuals with positive result who have no follow-up
- time to complete follow-up after a positive screen
- false positive and false negative rates
- cancer detection rates
- incidence and mortality rates of cancer in Ontario
<table>
<thead>
<tr>
<th>Outcome Indicator</th>
<th>Total OBSP Mammography</th>
<th>Canadian Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participation Rate† (%)</td>
<td>26.8</td>
<td>≥ 70% of eligible population</td>
</tr>
<tr>
<td>Retention Rate‡ (%)</td>
<td>81.4</td>
<td>≥ 75% rescreened within 30 months</td>
</tr>
<tr>
<td>Abnormal Call or Referral Rate (%)</td>
<td></td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Invasive Cancer Detection Rate (per 1000)</td>
<td></td>
<td>&gt; 5</td>
</tr>
<tr>
<td>Diagnostic Interval§ (%)</td>
<td></td>
<td>≥ 90% within 5 weeks without open biopsy</td>
</tr>
<tr>
<td>Positive Predictive Value (%)</td>
<td></td>
<td>≥ 5</td>
</tr>
<tr>
<td>Benign to Malignant Surgical Biopsy Ratio</td>
<td>0.5:1</td>
<td>≤ 2:1</td>
</tr>
<tr>
<td>Invasive Cancer Tumour Size &lt;= 10 mm (%)</td>
<td>38.1</td>
<td>&gt; 25</td>
</tr>
<tr>
<td>Positive Lymph Nodes (%)</td>
<td>22.3</td>
<td>&lt; 30% node positive</td>
</tr>
<tr>
<td>Post-Screen Detected Invasive Cancer Rate (per 10,000 person years)*</td>
<td>5.3</td>
<td>&lt; 6</td>
</tr>
</tbody>
</table>

Notes:
† Data for 2003 and 2004 screen years were used to calculate a biennial (2 year) participant rate. Both modalities of referral were considered.
‡ Percentage of women who last attended the OBSP in 2000 or 2001 with a two year screening recommendation who were rescreened within 30 months (i.e., up to 6 months after the recommended interval) of their previous screen. Both modalities of referral were considered.
What factors that support the implementation of programs across cancer types?

- There are common data elements that are needed for a comprehensive information system
  - Eligible population
  - Screening episode information
  - Follow-up assessment information
  - Outcome information
Why Do We Need Screening Information Systems and Registries?

<table>
<thead>
<tr>
<th>PROGRAMATIC COMPONENTS</th>
<th>PERFORMANCE &amp; PROGRAM MONITORING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recruit</strong> eligible population never screened or under-screened</td>
<td>Review participation rates, access to follow up tests, outcomes</td>
</tr>
<tr>
<td><strong>Recall</strong> individuals overdue for screening</td>
<td>Quality assurance</td>
</tr>
<tr>
<td><strong>Follow-up</strong> to ensure that individuals receive diagnostic procedures according to guideline</td>
<td>Performance feedback to practitioners</td>
</tr>
<tr>
<td></td>
<td>Public reporting provincially and nationally</td>
</tr>
</tbody>
</table>
### What Data Do We Need?

<table>
<thead>
<tr>
<th>The Test and Results of the Test</th>
<th>Cervical Screening</th>
<th>Breast Screening</th>
<th>Colorectal Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pap Test</td>
<td>Mammogram</td>
<td>Fecal Occult Blood Test (FOBT)</td>
<td></td>
</tr>
<tr>
<td>Colposcopy, Repeat Pap Tests, HPV Tests, Biopsies</td>
<td>Ultrasound, Special Mammograms, Needle Biopsy, Open Biopsy</td>
<td>Colonoscopy, Biopsies</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnostic Investigations and Results (cancer or no cancer)</th>
<th>Cervical Screening</th>
<th>Breast Screening</th>
<th>Colorectal Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ontario Women</td>
<td>Ontario Women</td>
<td>Ontario Women</td>
<td>Ontario Population Men and Women</td>
</tr>
</tbody>
</table>
Challenges and Issues for All Screening Programs

• How can we reach those at risk and not being screened?
• How can we avoid over-screening those not at risk?
• How can we more accurately measure how we are doing in provinces and Canada?
  – consistency in data,
  – common approaches to classification of screening test results,
  – national definitions of indicators
• How will we evaluate the added value of new technologies in screening?
  Does value =
  – reduction in burden of cancer?
  – better test qualities over previous tests e.g., Sensitivity?
  – improvement of efficiencies in our system by reduction of unnecessary screening and follow-up?
• Ensuring existing systems are continuously reviewed & upgraded to meet growing needs
What factors that support the implementation of programs across cancer types?

• Common target population: Healthy population
  – Commonalities of subpopulations also across some cancer types e.g., gender (cervix, breast, and colorectal in women; over 50 age group for initiating breast and colorectal)

• Common barriers to screening behavior exist for breast and cervical screening (and likely colorectal too) for
  – the target populations and
  – primary care physicians – who do recommend screening for all cancer types
<table>
<thead>
<tr>
<th>Reason</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Didn’t think necessary</td>
<td>34.1%</td>
</tr>
<tr>
<td>Have not gotten around to it</td>
<td>27.1%</td>
</tr>
<tr>
<td>Doctor didn’t think necessary</td>
<td>20.9%</td>
</tr>
</tbody>
</table>
Why Ontario Women Have Not Had a Pap Test in the Past 3 years (CCHS, 2003)

Didn’t think it was necessary 29.1%

Have not gotten around to it 23.3%

Doctor didn’t think it was necessary 15.9%
Family Physicians’ Perceived Barriers to Providing Recommended Screening to Women
(Hutchison et al, 1996)

- Patient is healthy and does not visit
- Patient refuses or is not interested
- No effective patient reminder systems
- Priority is given to presenting problems
- No system to remind physicians about preventive services
- Not enough time during patient visits to address
- Intervention not clearly effective
- Intervention causes patient discomfort or inconvenience
Family Health Teams Preventive Care
Payment Incentives in Ontario Established for
Breast, Cervical and Colorectal Screening

Mammogram: Service Enhancement Fee (annual)

<table>
<thead>
<tr>
<th>% of Enrolled Patients (between 50-70)</th>
<th>Fee Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>55%</td>
<td>$220</td>
</tr>
<tr>
<td>60%</td>
<td>$440</td>
</tr>
<tr>
<td>65%</td>
<td>$770</td>
</tr>
<tr>
<td>70%</td>
<td>$1,320</td>
</tr>
<tr>
<td>75%</td>
<td>$2,200</td>
</tr>
</tbody>
</table>
## Family Health Teams Preventive Care Payment Incentives

### Cervical: Service Enhancement Fee (annual)

<table>
<thead>
<tr>
<th>% of Enrolled Patients</th>
<th>Fee Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>60%</td>
<td>$ 220</td>
</tr>
<tr>
<td>65%</td>
<td>$ 440</td>
</tr>
<tr>
<td>70%</td>
<td>$ 770</td>
</tr>
<tr>
<td>75%</td>
<td>$1,320</td>
</tr>
<tr>
<td>80%</td>
<td>$2,200</td>
</tr>
</tbody>
</table>
Family Health Teams Preventive Care Payment Incentives

Colorectal: Service Enhancement Fee (annual)

<table>
<thead>
<tr>
<th>% of Enrolled Patients</th>
<th>Fee Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>15%</td>
<td>$ 220</td>
</tr>
<tr>
<td>20%</td>
<td>$ 440</td>
</tr>
<tr>
<td>40%</td>
<td>$1,100</td>
</tr>
<tr>
<td>50%</td>
<td>$2,200</td>
</tr>
</tbody>
</table>
What factors that support the implementation of programs across cancer types?

• Stakeholders in primary care, health promotion and health education address all types of cancer screening in their communities
  – A cancer screening message overall could have a more holistic approach to screening, rather than separating each body parts

• What about new screening tests for cancer that apply to more than one cancer type?
“In the small world of people who train dogs to sniff cancer, a little-known Northern California clinic has made a big claim: that it has trained five dogs – three labradors and two Portuguese water dogs – to detect lung cancer in the breath of cancer sufferers with 99 percent accuracy.”

(For breast cancer, with a smaller number of samples, the dogs were right about 88 percent of the time with almost no false positives, which compares favorably to mammograms)

Dr. Berry, too, was interested but suspicious. “If true, it’s huge,” he said. “Which is one reason to be skeptical.”
What are the factors that support the implementation of programs across cancer types?

• Consolidation of the key messages across cancer types would be helpful:
  – what types of cancer screening are supported by scientific evidence and what types of screening are not (and therefore, are not part of the cancer screening program), to reinforce the message that **effective screening reduces the risk of death from certain cancer types**.

  – **pro’s and con’s of screening** based on the science behind screening to support informed decision-making for all types of cancer screening
What is the Best Evidence of Effectiveness of a Screening Test?

• Therapeutic benefit that has been demonstrated by experimental evidence from randomized trials.
Is Early Detection Always Better?

- **Lead time bias** (in survival time)
  - lead time is the interval between the time of detection by screening and the time at which the disease would have been diagnosed in the absence of screening
  - because of the lead time, all individuals with disease identified as a result of screening will have a longer survival time than those diagnosed in the normal way

- **Length time bias:**
  - Less rapidly progressing cancers will not progress to symptomatic stages quickly and be more likely to be found by screening vs. more aggressive cancers. Thus better outcomes seen in screen-detected vs. non-screen detected tumors

- **Selection bias**
- **Overdiagnosis bias**
Other Potential Negative Effects of Screening

- **False positive test results** (needless anxiety and follow-up investigations in asymptomatic, healthy individuals)
- **False negative test results** (patient has the disease, but this is not detected by the screening test; false sense of security)
- **Complications from the testing** (e.g., perforation of the colon from colonoscopy follow-up for FOBT positives)
- **Labeling** (the damage done when we tell someone who feels well that they are sick)
What are the barriers to implementation of programs across cancer types?
What are the barriers to implementation of programs across cancer types?

• Different Body Sites with differing
  – cancers that can occur
  – emotions and stigma attached to them–
  Screening promotion and recruitment approaches need to be tailored appropriately

• Different screening tests carried out in different ways (target age groups, intervals)

• Different “testers” (family doctor- Pap, radiologist- mammogram, patient home test- FOBT) processed and reported on by different health care providers.

• Different specialists doing follow-up investigations, each group with their own community of practitioners: radiologists, gastroenterologists, gynecologists
What are the barriers to implementation of programs across cancer types?

• While basic screening performance indicators may be similar, **cancer type specific indicators and benchmarks** must be developed and analyzed by those who are expert in quality issues specific to the cancer type.

• Therefore, a challenge to integrate breast, cervical and colorectal programs into one “cancer screening program” -- each cancer type will still need to have **expert program committees** to deal with quality issues specific to the cancer site.
Mammogram Accreditation by the Canadian Association of Radiologists (CAR-MAP)

CAR-MAP sets standards for:

- equipment
- image quality
- radiology staff skills and qualifications
Colonoscopy Standards

• Expert Panel in Ontario, involving gastroenterologists
• What settings can colonoscopy be performed in?
  – Resources needed for best outcomes:
    • Infection control
    • Patient monitoring during and after procedure
    • Resuscitation capacity
    • Equipment standards
    • Evaluation and audit programs
Gynecologic Cytology Quality Assurance

Cytology lab standards, training and qualifications, rescreening, proficiency testing
What are the barriers to implementation of programs across cancer types?

• **Separate funding envelopes** exist for the different cancer screening programs and initiatives and these have been established at different times, based on program proposals developed for one cancer type.
  – Getting new programs for the healthy population through policy and funding decisions is a challenge

• **Cost issues** –
  – for new colorectal screening programs and for
  – “retrofitting” existing programs into a new integrated model, including common IT population-based system.
Where does that leave us?? ……opportunities for action:

• **Health promotion and education initiatives**, providing consistent, consolidated materials for public health nurses and primary care physicians, nurse practitioners – including pro’s and con’s of screening, to support informed participation.

• **Performance reporting** on cancer screening for breast, cervical and colorectal cancer sites should develop a common set of indicators, building on the extensive work in breast screening evaluation indicators.

• With the capability of new information technology, evolution towards **comprehensive information systems**. As the rest of the health care system has become very interested in performance reporting, including wait times, and recognized the need for more population oriented data, there are opportunities to tie screening information system improvements into the bigger system initiatives.

• Utilize the opportunities that present with the interest shown in colorectal screening to foster an integrated cancer screening strategy, and strengthen the existing programs.
“must do’s” to ensure programmatic screening is supported

• Find more effective ways to make the case to funders (government) for organized screening programs for breast, colorectal and cervical screening – in terms of economic benefit. This requires a shift from “health benefits” (e.g., # of deaths prevented) to “# of dollars saved” in the system (timing and cost-effectiveness, costs averted)

• Tie programmatic screening initiatives into the “bigger picture” health care initiatives in your jurisdictions
  • Primary Care Reform
  • Wait Times Benchmarks

• Education campaign to ensure that there is a good understanding of the difference between opportunistic/adhoc screening and organized programmatic screening; and principles of screening.
### Key Components of Organized Screening Programs

<table>
<thead>
<tr>
<th>Population-Based recruitment of eligible population e.g., Letter of invitation</th>
<th>Population Information Systems</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>target population</td>
</tr>
<tr>
<td></td>
<td>screening data</td>
</tr>
<tr>
<td></td>
<td>follow-up data</td>
</tr>
<tr>
<td></td>
<td>results of screening &amp; follow-up</td>
</tr>
<tr>
<td></td>
<td>cancer and non-cancer outcomes</td>
</tr>
</tbody>
</table>

| Evidence-based screening guidelines that are routinely reviewed & updated as new evidence emerges and implemented |
| Quality assurance programs in screening “right test given to right persons at the right timing” |
| Monitoring and evaluation of the impact of screening |
| Health promotion initiatives & evidence-based health education materials to support primary care and public health |

| Accessibility/coverage |
| Diagnostic test utilization |
| Yield, positive predictive values |
| Timelines of screening pathways |
| Screening outcomes |
Models That May be Considered

<table>
<thead>
<tr>
<th>Opportunistic Screening (current situation)</th>
<th>Focus on Development of Health Promotion &amp; Educational Material Only</th>
<th>Focus On Primary Care Reforms Only (Family Health Networks)</th>
<th>Guideline Development &amp; Dissemination With Measurement of Practice Patterns and guideline adherence</th>
<th>Fully Organized Program</th>
</tr>
</thead>
</table>
Dealing With New, Promising Screening Technology

• Screening is a thriving industry - with many new technologies in production, some site-specific, some non-specific
Hand Held Optical Scanner for Early Detection of Breast Cancer

• a “first-line”, affordable and easy to use mass screening
• available to the general population over the counter without a prescription.

**NIRScanner™ as a Personal Health Care Device**

- **self-examination tool** to complement periodic breast palpation.
- The NIRScan provides *real-time, direct numerical and audible read out* of the subsurface cancer location. The data is recorded in a computer or PDA for subsequent reading by the mammographer.
- Based on pre-clinical tests (100 subjects to date) using laboratory prototypes, NIRScan provides **92% expectancy of correct diagnosis**. This ROC (a measure of cancer discriminating capacity) is comparable to MRI and PET, **hence better than X-Ray mammography**.
The right time....
the right procedure.

While colorectal cancer is a highly treatable and preventable disease, **patient resistance to the traditional diagnostic techniques** means that only a small portion of those who should be tested actually are.

**The time to begin colorectal cancer screening of the general population aged 50 and over – with an examination that studies the entire bowel – is now.**

**With tens of millions of prospective patients, colorectal cancer screening represents a significant opportunity for the right diagnostic technology.**
If you’re a gambling woman, then getting just a Pap test is fine.

Almost all cervical cancers are caused by a virus—the human papillomavirus (HPV). A Pap test looks for the abnormal cells caused by HPV but may not find them until it is too late. Only the HPV test can directly detect the virus and is nearly 100% accurate.

When used along with a Pap, the HPV test can help your doctor reduce your chance of identifying cervical cancer and is approved for screening women 30 and over.

Learn more before your next doctor’s appointment.

www.thehpvtest.com 877-HPV-FACT

Oncotype DX, makes the only FDA-approved HPV test for detection of high-risk HPV associated with cervical cancer. Include it in your next Pap test. The HPV test is not a substitute for regular Pap screening, and it is not standard of care in women younger than 20 with.

cancer care ontario  action cancer ontario
Conclusion

• There are definitely opportunities for integration
• Some of the programmatic barriers to integration need careful thought to determine which elements can be combined and when there must be unique cancer site specific elements.
• Integration can streamline cancer screening and strengthen cancer screening programs.
• Providing a sound basis for a “cancer screening program” can help us all tackle the evaluation of new technologies and provide key screening messages (regardless of cancer site) with a consistent approach
• Building a stronger foundation for justifying programmatic screening is needed – vs.. encouraging adhoc process improvements in the system.